36 results
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
and their impact on Adaptimmune’s and TCR2’s respective businesses, operations, supply chain, patient enrollment and retention, preclinical and clinical trials
425
TCRR
Tcr2 Therapeutics Inc
30 May 23
Business combination disclosure
4:21pm
health crises and their impact on Adaptimmune’s and TCR2’s respective businesses, operations, supply chain, patient enrollment and retention
8-K
h5ai1j kwu
30 May 23
Submission of Matters to a Vote of Security Holders
4:18pm
425
bfo3am pk
22 May 23
Business combination disclosure
7:01am
8-K
ecdoc9fy0p0cf ejz19
22 May 23
Other Events
6:59am
8-K
EX-99.1
nhz327t
12 May 23
Adaptimmune Reports First Quarter Financial Results and Business Update
7:36am
424B3
gi97m0e7a dv16
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
1zbjpivpu vidx
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
8-K
EX-10.1
3nsxm kl9edok
11 Apr 23
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
8:08am
S-4
c196jg42sf4pj6mt8uq
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm